Literature DB >> 31942657

Noninvasive positive pressure ventilator deteriorates the outcome of pneumomediastinum in anti-MDA5 antibody-positive clinically amyopathic dermatomyositis.

Mengmeng Zhou1, Yan Ye1, Ninghui Yan1, Xinyue Lian1, Chunde Bao2, Qiang Guo3.   

Abstract

BACKGROUND: Anti-melanoma differentiation-associated gene 5 (MDA5) antibody (Ab)-positive clinically amyopathic dermatomyositis (CADM) with pneumomediastinum (PNM) is a life-threatening condition. We aim to determine the prognostic factors affecting survival of patients with anti-MDA5 Ab-positive CADM complicated with PNM.
METHODS: We retrospectively established a cohort of patients with anti-MDA5 Ab-positive CADM complicated with PNM from April 2013 to July 2019. Demographic data and clinical characteristics from medical records were analyzed and variables were compared between survivors and nonsurvivors. We performed univariate and multivariate survival analyses by Cox regression. Survival curves were depicted by the Kaplan-Meier method.
RESULTS: Among 133 patients with anti-MDA5 Ab-positive CADM, 20 were diagnosed with PNM. The cumulative estimated Kaplan-Meier survival rate was 85% at 1 week, 55% at 1 month, and 40% at 1 year. Univariate analysis indicated several factors associated with survival. Worse liver function (AST, p = 0.043; LDH, p = 0.002; TBIL, p = 0.038), higher CRP level (p = 0.044), higher HRCT score (p = 0.022), and using noninvasive positive pressure ventilation (NPPV) (p < 0.01) were associated with poor prognosis. In a multivariate Cox regression model, AST level and using NPPV were indicated to be independent predictors of poor prognosis.
CONCLUSION: In this research, we found that the incidence rate of PNM in anti-MDA5 Ab-positive CADM was 15.5%, obviously higher than in classical DM. The application of noninvasive positive pressure ventilator (NPPV) and higher AST level were independent risk factors for survival.Key Points• Anti-MDA5 Ab-positive CADM complicated with PNM is a life-threatening condition with an incidence rate of 15.5%.• The application of NPPV and worse liver function were independent risk factors for survival of anti-MDA5 Ab-positive CADM patients complicated with PNM.

Entities:  

Keywords:  Clinically amyopathic dermatomyositis; MDA5; Pneumomediastinum; Prognosis

Mesh:

Substances:

Year:  2020        PMID: 31942657     DOI: 10.1007/s10067-019-04918-2

Source DB:  PubMed          Journal:  Clin Rheumatol        ISSN: 0770-3198            Impact factor:   2.980


  30 in total

Review 1.  Amyopathic dermatomyositis: definitions, diagnosis, and management.

Authors:  Elizabeth E Bailey; David F Fiorentino
Journal:  Curr Rheumatol Rep       Date:  2014-12       Impact factor: 4.592

2.  Tofacitinib in Amyopathic Dermatomyositis-Associated Interstitial Lung Disease.

Authors:  Zhiwei Chen; Xiaodong Wang; Shuang Ye
Journal:  N Engl J Med       Date:  2019-07-18       Impact factor: 91.245

Review 3.  Dermatomyositis.

Authors:  J P Callen
Journal:  Lancet       Date:  2000-01-01       Impact factor: 79.321

4.  Clinical and serological features of patients with dermatomyositis complicated by spontaneous pneumomediastinum.

Authors:  Xiaolei Ma; Zhiyong Chen; Wei Hu; Ziwei Guo; Yan Wang; Masataka Kuwana; Lingyun Sun
Journal:  Clin Rheumatol       Date:  2015-07-07       Impact factor: 2.980

5.  Amyopathic dermatomyositis developing rapidly progressive interstitial lung disease with elevation of anti-CADM-140/MDA5 autoantibodies.

Authors:  Shinji Sato; Masataka Kuwana; Takashi Fujita; Yasuo Suzuki
Journal:  Mod Rheumatol       Date:  2011-11-29       Impact factor: 3.023

6.  Mediastinal emphysema: aetiology, diagnosis, and treatment.

Authors:  J M Gray; G C Hanson
Journal:  Thorax       Date:  1966-07       Impact factor: 9.139

Review 7.  Clinically amyopathic dermatomyositis.

Authors:  Shinji Sato; Masataka Kuwana
Journal:  Curr Opin Rheumatol       Date:  2010-11       Impact factor: 5.006

8.  Predictive factors of rapidly progressive-interstitial lung disease in patients with clinically amyopathic dermatomyositis.

Authors:  Y Xu; C S Yang; Y J Li; X D Liu; J N Wang; Q Zhao; W G Xiao; P T Yang
Journal:  Clin Rheumatol       Date:  2015-12-10       Impact factor: 2.980

9.  Rapidly progressive interstitial lung disease due to anti-MDA-5 antibody-positive clinically amyopathic dermatomyositis complicated with cervical cancer: Successful treatment with direct hemoperfusion using polymyxin B-immobilized fiber column therapy.

Authors:  Hidenori Ichiyasu; Yasumiko Sakamoto; Chieko Yoshida; Kazuhiko Sakamoto; Ryosuke Fujita; Go Nakayama; Hiroko Okabayashi; Sho Saeki; Shinichiro Okamoto; Hirotsugu Kohrogi
Journal:  Respir Med Case Rep       Date:  2016-12-02

Review 10.  Dyspnoea and chest pain as the presenting symptoms of pneumomediastinum: two cases and a review of the literature.

Authors:  Hasan Kara; Hasan Gazi Uyar; Selim Degirmenci; Aysegul Bayir; Murat Oncel; Ahmet Ak
Journal:  Cardiovasc J Afr       Date:  2015-10-08       Impact factor: 1.167

View more
  7 in total

Review 1.  Interstitial Lung Disease in Anti-MDA5 Positive Dermatomyositis.

Authors:  Wanlong Wu; Li Guo; Yakai Fu; Kaiwen Wang; Danting Zhang; Wenwen Xu; Zhiwei Chen; Shuang Ye
Journal:  Clin Rev Allergy Immunol       Date:  2021-01-06       Impact factor: 8.667

2.  A New Predictive Model for the Prognosis of MDA5+ DM-ILD.

Authors:  Qian Niu; Li-Qin Zhao; Wan-Li Ma; Liang Xiong; Xiao-Rong Wang; Xin-Liang He; Fan Yu
Journal:  Front Med (Lausanne)       Date:  2022-06-15

3.  Interstitial lung disease with anti-melanoma differentiation-associated gene 5 antibody after allogeneic hematopoietic stem cell transplantation.

Authors:  Masaharu Tamaki; Shimpei Matsumi; Hideki Nakasone; Yuhei Nakamura; Masakatsu Kawamura; Shunto Kawamura; Junko Takeshita; Nozomu Yoshino; Yukiko Misaki; Kazuki Yoshimura; Ayumi Gomyo; Aki Tanihara; Yosuke Okada; Machiko Kusuda; Kazuaki Kameda; Shun-Ichi Kimura; Shinichi Kako; Yoshinobu Kanda
Journal:  Bone Marrow Transplant       Date:  2022-06-04       Impact factor: 5.174

Review 4.  Understanding and managing anti-MDA 5 dermatomyositis, including potential COVID-19 mimicry.

Authors:  Pankti Mehta; Pedro M Machado; Latika Gupta
Journal:  Rheumatol Int       Date:  2021-03-27       Impact factor: 2.631

5.  The Expression of Cytokine Profiles and Related Receptors in Idiopathic Inflammatory Myopathies.

Authors:  Junyu Zhou; Lijuan Zhao; Yizhi Xiao; Shasha Xie; Ying Long; Yu Wei; Qiming Meng; Xiaojing Li; Hui Luo; Honglin Zhu
Journal:  Front Pharmacol       Date:  2022-04-20       Impact factor: 5.988

6.  A Man With Malaise, Myalgia, and Rapidly Progressive Interstitial Lung Disease.

Authors:  Marissa O'Callaghan; Leah Rooney; Jehangir Khan; Sinead Flanagan; Michael P Keane; Aurelie Fabre; Lorraine O'Neill; Cormac McCarthy
Journal:  Chest       Date:  2022-09       Impact factor: 10.262

7.  The clinical features and prognoses of anti-MDA5 and anti-aminoacyl-tRNA synthetase antibody double-positive dermatomyositis patients.

Authors:  Xixia Chen; Lu Zhang; Qiwen Jin; Xin Lu; Jieping Lei; Qinglin Peng; Guochun Wang; Yongpeng Ge
Journal:  Front Immunol       Date:  2022-08-30       Impact factor: 8.786

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.